Comparison · NCT01802775-3eeeccef
Clopidogrel vs Edoxaban: Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Clopidogrel vs Edoxaban: Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period. Trial comparisons, record NCT01802775-3eeeccef. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01802775-3eeeccef
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0099 | 0.00175 | 0.054 | wilson | |
| Risk in group 2 | 0.03 | 0.0103 | 0.0845 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0201 | -0.0752 | 0.0282 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.33 | 0.0349 | 3.12 | log | |
| Odds ratio, group 1 over group 2 | 0.323 | 0.0331 | 3.16 | log | |
| Number needed to treat, for one fewer participant with the outcome on Clopidogrel than on Edoxaban | 49.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Clopidogrel | Open-label clopidogrel with aspirin | 1 | 101 | OG000 |
| Group 2 | Edoxaban | Open-label edoxaban with aspirin | 3 | 100 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period
- Description
- Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death
- Time frame
- within 6 months
- Population
- mITT Set 1 (Safety Analysis Set), defined as the participants who received at least 1 dose of study drug
Source ClinicalTrials.gov
Trial
- Title
- Edoxaban in Peripheral Arterial Disease
- NCT number
- NCT01802775
- Phases
- PHASE2
- Conditions
- Peripheral Arterial Disease
- Interventions
- edoxaban, Clopidogrel, Aspirin
- Lead sponsor
- Daiichi Sankyo
- Results first posted
- 2018-01-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01802775?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01802775-3eeeccef